Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
370 results
  • StatPearls: Alosetron [BOOK]
    StatPearls. StatPearls Publishing: Treasure Island (FL)ButtIfrahIAventura Hospital and Medical CenterKasminFranklinFMount Sinai School of MedicineBOOK
  • Alosetron is a medication used to manage and treat severe diarrhea-predominant irritable bowel syndrome (IBS-D). It is in the class of 5-HT receptor antagonist medications. This activity outlines the indications, action, and contraindications for alosetron as a valuable agent in IBS-D management. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e…
  • A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers. [Review]
    Adv Ther. 2022 09; 39(9):4003-4020.Moshiree B, Heidelbaugh JJ, Sayuk GS
  • Irritable bowel syndrome with diarrhea (IBS-D) is a chronic disorder of gut-brain interaction, characterized by recurrent abdominal pain in association with more frequent, loose stools. The pathophysiology of irritable bowel syndrome (IBS) includes disordered gut motility, alterations in gut microbiota, neural-hormonal system abnormalities, immune reactivity, and visceral hypersensitivity. Timely…
  • Best management of irritable bowel syndrome. [Review]
    Frontline Gastroenterol. 2021; 12(4):303-315.Black CJ, Ford AC
  • Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction which can have a considerable impact on quality of life. Following diagnosis, timely and evidence-based management is vital to the care of patients with IBS, aiming to improve outcomes, and enhance patient satisfaction. Good communication is paramount, and clinicians should provide a clear explanation about the disorder,…
  • An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. [Review]
    Expert Opin Drug Metab Toxicol. 2020 Jul; 16(7):583-604.Mousavi T, Nikfar S, Abdollahi M
  • CONCLUSIONS: Anti-spasmodics are used as the first-line treatment in pain-predominant IBS and IBS-D, among which calcium channel blockers and neurokinin-type 2 receptor antagonists seem to replace anti-cholinergic drugs. As second-line treatments, rifaximin is considered to be the best for IBS-D though it has lower efficacy than alosetron and eluxadoline. For IBS-C, linaclotide is the most effective and the safest second-line therapy, following laxatives/fibers, which may be replaced by tenapanor, in the future. When moderate to severe IBS is associated with severe pain or comorbid psychological disorders, gut-brain neuromodulators could also be prescribed. Regarding all this, there is still a paramount need to conduct careful clinical studies on efficacy, safety and cost-effectiveness of current approved and non-approved treatments.
  • Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome. [Review]
    Expert Opin Pharmacother. 2020 Jan; 21(1):63-71.Munjal A, Dedania B, Cash BD
  • Introduction: Irritable bowel syndrome with diarrhea (IBS-D) is among the most common functional gastrointestinal (GI) disorders and is associated with impaired quality of life, increased health-care utilization, and significant costs to patients and society. The treatment of IBS is typically hierarchal with initial therapies consisting of dietary and lifestyle modifications. Pharmacotherapy with…
New Search Next